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Abstract
The precursor of the non-amyloid L/A4 protein (non-AL) component of Alzheimer’s disease amyloid (NACP)/K-synuclein
is the human homologue of K-synuclein, a member of a protein family which includes K-, L- and Q-synuclein. This protein is
thought to be involved in neuronal plasticity because of its unique expression, mainly in the telencephalon during
maturation. Consequently, disarrangement of NACP/K-synuclein might disrupt synaptic activity, resulting in memory
disturbance. Previous studies have shown that damage to synaptic terminals is closely associated with global cognitive
impairment and is an early event in the pathogenesis of Alzheimer’s disease. Although the relationship between synaptic
damage and amyloidogenesis is not clear, some proteins at the synaptic site have been implicated in both neuronal alteration
and amyloid formation. Indeed, abnormal accumulation of both NACP/K-synuclein and AL precursor protein occurs at
synapses of Alzheimer’s patients. Other evidence suggests that NACP/K-synuclein is a component of the Lewy bodies found
in patients with Parkinson’s disease or dementia with Lewy bodies, and that a point mutation in this protein may be the cause
of familial Parkinson’s disease. Consequently, abnormal transport, metabolism or function of NACP/K-synuclein appears to
impair synaptic function, which induces, at least in part, neuronal degeneration in several neurodegenerative
diseases. ß 2000 Published by Elsevier Science B.V.
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1. Precursor of non-amyloid L/A4 protein (non-AL)
component of Alzheimer’s disease amyloid
(NACP)/K-synuclein is a presynaptic protein and its
physiological role is associated with synaptic
function
NACP/K-synuclein proteins were independently
identi¢ed by four di¡erent groups. Reports by Mar-
oteaux et al. ¢rst described a highly-abundant pro-
tein found in the electric organ of the Paci¢c electric
ray (Torpedo californica) [1]. This protein was named
‘synuclein’ based on initial ¢ndings indicating both
synaptic and nuclear distribution. Additionally, three
related sequences were found in a rat brain cDNA
library; these were named SYN1, SYN2 and SYN3
[2]. However, subsequent studies failed to con¢rm
that synuclein is localized in the nucleus [3^5]. In
1993, Ue¤da et al. identi¢ed a 35 amino acid residue
peptide found in the SDS-insoluble fraction from the
brain tissue of patients with Alzheimer’s disease and
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named this peptide the non-AL component of Alz-
heimer’s disease amyloid (NAC) [6]. Subsequently, a
cDNA coding the NACP protein was discovered and
sequenced [6]; this analysis revealed NACP to be the
human homologue of synuclein [3,4]. An alterna-
tively spliced mRNA has been isolated from human
tissues, indicating the NACP/K-synuclein gene under-
goes tissue-dependent alternative splicing [7]. In 1994
[3], two proteins in human brain tissue, initially iden-
ti¢ed by a monoclonal antibody raised against paired
helical ¢laments known as neuro¢brillary tangles,
were found to be the human homologues of synu-
clein ( = NACP), and phosphoneuroprotein 14 (PNP-
14), the latter being a 14 kDa phosphoneuroprotein
found in bovine brain tissue identi¢ed by Nakajo et
al. [8]. These human proteins were named K-synu-
clein and L-synuclein by Jakes et al. and this nomen-
clature has been widely used since [3]. In 1995,
George et al. also cloned and sequenced a zebra ¢nch
homologue of NACP/K-synuclein which they named
synel¢n [5].
In addition to K- and L-synuclein, a third human
synuclein, Q-synuclein, was also identi¢ed. The breast
cancer speci¢c gene 1 (identi¢ed by a direct-di¡er-
ential cDNA sequencing approach [9]), persyn [10]
and their rat homologue [11] have been identi¢ed
as Q-synucleins. Recently, a novel Q-synuclein mem-
ber, synoretin, mainly expressed in the outer nuclear
layer of the retina as well as the brain, has been
identi¢ed and shown to be a¡ected by the regulation
of signal transduction through activation of the Elk1
pathway [12]. Fig. 1 shows the amino acid sequences
of the three human synucleins and related proteins.
The NACP/K-synuclein sequence has been extremely
well conserved among vertebrates [1^3,5,6,8^12].
NACP/K-synuclein is composed of 140 amino acid
residues. It is a heat-stable protein mainly found in
the soluble fraction of human brain homogenates.
NACP/K-synuclein has neither a signal peptide se-
quence nor N-linked glycosylation sites. Seven re-
peats of the 6-residue ‘KTKEGV’ motif are located
in the N-terminal half of the protein, but the phys-
iological signi¢cance of this motif is unknown [6]. It
has been predicted that this motif forms an amphi-
pathic K-helix structure typical of the lipid-binding
domain of apolipoproteins [5]. NACP/K-synuclein
has approximately 60% overall homology to L-synu-
clein. NACP/K- and L-synucleins are found in equal
abundance in the brain and together comprise ap-
proximately 0.1% of its soluble protein. The NAC
peptide fragment which accumulates in Alzheimer’s
disease amyloid consists of residues 61 to 95 of
NACP/K-synuclein, which is a highly hydrophobic
portion. Additionally, although the central portion
of NACP/K-synuclein includes the NAC peptide
fragment, those of L- and Q-synuclein do not include
the NAC sequence. Therefore, the precursor of NAC
is probably NACP/K-synuclein. However, since Ach-
romobacter lyticus protease, which cuts the peptide
bond C-terminal to lysine, was used during NAC
puri¢cation, the N-terminal residue of NAC remains
undetermined. As no other fragments of NACP/K-
synuclein except NAC were found in the SDS-insolu-
ble fraction, these 35 amino acids were considered to
be the minimal fragment of the peptide found in
Alzheimer’s disease amyloid, even though a ‘full-
length’ NAC in amyloid might be slightly longer at
its N-terminal end [6]. The N-terminal halves of
NACP/K-synuclein, L-synuclein and Q-synuclein are
highly conserved. However, while the residues near
the C-terminal end of NACP/K-synuclein are similar
to those of L-synuclein, those of Q-synuclein diverge
greatly from the NACP/K-synuclein sequence.
The human NACP/K-synuclein gene has been
mapped to chromosome 4q21.3-q22 [13^17]. While
the mRNA of NACP/K-synuclein is abundant in
the brain, it has also been detected in the placenta,
lungs and kidneys [6]. NACP/K-synuclein protein in
the brain is distributed in a unique pattern. Both
immunohistochemical and biochemical data have
demonstrated that NACP/K-synuclein is relatively
abundant in the telencephalon including the olfac-
tory bulb, cerebral cortex, striatum and hippocam-
pus; the molecular layer and the granular layer in the
cerebellum and the substantia nigra [4]. Additionally,
it is expressed moderately in the thalamus [4]. Elec-
tron microscopic studies found NACP/K-synuclein
associated with the synaptic vesicles of the presynap-
tic terminals [4]. This distribution was similar to that
of synaptophysin, identi¢ed by mouse monoclonal
antibody SY38 [18]. Synaptophysin is a synaptic
vesicle protein commonly used as a ‘presynaptic
marker’ in experiments [19,20]. Double immuno-
staining with anti-NACP/K-synuclein and anti-synap-
tophysin suggests that NACP/K-synuclein is also spe-
ci¢c to presynaptic terminals and may have a role in
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Fig. 1. Amino acid sequence analysis of synuclein gene family members, aligned for maximum. Amino acids identical in all proteins
or all but one protein are shown by the shaded areas. Gaps (^) are introduced for better alignment. The ‘KTKEGV’ motif repeats
are outlined with Roman numerals above bars. The NAC peptide fragment found in Alzheimer’s disease amyloid is denoted by the
line. The mutations (P30 for A30 or T53 for A53) found in the familial Parkinson’s disease are boxed.
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some mobilization of synaptic vesicles. Because syn-
aptophysin is an integral synaptic vesicle membrane
protein, it is detected in the particulate fractions of
brain homogenate in Western blot analysis [18].
However, NACP/K-synuclein is found mainly in the
cytosolic or soluble fraction [4,6]. Therefore, it is
possible that NACP/K-synuclein is loosely associated
with the membrane or membrane-binding proteins of
synaptic vesicles [4]. PNP-14/L-synuclein shows al-
most the same distribution in the brain as NACP/
K-synuclein [21]. It is thought that both proteins are
transported by fast axonal transport after synthesis
in the cell body and immediately assembled in the
vicinity of the synaptic vesicle [22]. Size determina-
tion using gel ¢ltration demonstrates that both
NACP/K-synuclein and PNP-14/-synuclein form
homo-tetramers in vivo [8,23]. The hydrophobic do-
main of NACP/K-synuclein, including the NAC por-
tion, is thought to be in the region responsible for
this proposed association with the synaptic vesicles,
but the details remain unclear. It has been reported
that this protein preferentially associates with smaller
diameter unilamellar phospholipid vesicles (20^25
nm) as opposed to larger (125 nm) vesicles and its
binding to the lipid layer increases K-helicity [24].
Although the physiological function of NACP/K-
synuclein is unknown, its presynaptic distribution
and conserved sequence suggest it is intimately in-
volved in synaptic function. Expression of NACP/
K-synuclein is minimal in the embryonic rat brain
but increases during development [25]. It appears in
cultured rat hippocampal cells several days later than
the appearance of synapsin immunoreactivity [26].
These results suggest that NACP/K-synuclein is not
a constitutive synaptic component, but its expression
might be induced during the formation of neuronal
circuits after initial synaptogenesis. Indeed, synel¢n
(zebra ¢nch K-synuclein) is induced during the crit-
ical period when juvenile zebra ¢nches learn songs
and the song control circuit in the telencephalon is
organized [27]. On the basis of these ¢ndings, Clay-
ton and George have hypothesized that induction,
localization and function of this protein might be
subject to regulation by signals associated with syn-
aptic activity, neuronal growth or both, and that
NACP/K-synuclein plays an important role in neuro-
nal plasticity [28].
Additionally, although it has been recently re-
ported that synucleins regulate phospholipase D2 ac-
tivity, the signi¢cance of the roles that this protein
plays in neuronal development and function remains
unclear [29]. Although several proteins associated
with NACP/K-synuclein, which could possibly be
used to delineate the function of NACP/K-synuclein,
have been studied, no clear results have been con-
¢rmed.
2. Synaptic dysfunction can cause pathological
changes in Alzheimer’s disease
Alzheimer’s disease is a progressive neurodegener-
ative disorder, whose pathology is marked by the
presence of intracerebral and cerebrovascular amy-
loid deposits and neuro¢brillary tangles. Amyloid
deposits at the core of senile plaques and on vessel
walls have been regarded as one of the most impor-
tant pathological changes in Alzheimer’s disease [30^
34]. Indeed, studies on persons with Down’s syn-
drome associated with trisomy of chromosome 21
who commonly develop pathological changes associ-
ated with Alzheimer’s disease, show that the earliest
histopathological change is the deposition of amyloid
[35]. Consequently, much research on amyloid as a
causative factor has been carried out. However, re-
cent studies have pointed to the importance of exten-
sive synaptic degeneration and loss in neurodegener-
ative diseases [36^42], and have prompted a novel
working hypothesis which can explain both amyloid
and synaptic abnormality.
The signi¢cance of synaptic disconnection in Alz-
heimer’s disease has been reviewed by Masliah [43].
To recapitulate, the dementia associated with Alz-
heimer’s disease can be directly correlated with the
disruption of neuronal substructure and the loss of
synaptic connections in speci¢c neocortical, limbic
and subcortical areas [42,44]. Measurements taken
using both electron microscopic and immunocyto-
chemical techniques have shown strong correlation
between the number of synapses in the frontal cortex
and test scores of global cognition in Alzheimer’s
disease patients [37,45]. More recently, studies corre-
lating cognition test scores with the presence of var-
ious synaptic proteins, assessed immunohistochemi-
cally, have con¢rmed this view [40,46,47].
In addition to these results, synaptic change also
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appears to be an early event in Alzheimer’s pathol-
ogy. It has been shown that in very early stages in
the progression of Alzheimer’s disease, a mild synap-
tic loss occurs in the outer molecular layer of the
dentate gyrus which is accompanied by abnormal
tau protein and AL precursor protein (APP) immu-
noreactivity in the entorhinal cortex, as well as dif-
fuse amyloid deposition in this region. As the disease
develops, neuro¢brillary tangles form, ¢rst in the
limbic system and then in the neocortex, accompa-
nied by the formation of neuritic plaques. At this
point the synaptic pathology accelerates [48^50].
These results suggest that altered function in vulner-
able neurons results in synaptic loss, which in turn is
associated with cognitive dysfunction and amyloid
deposition. However, it is not yet known whether
AL deposition is the initial trigger or not. Although
it has not been conclusively determined whether syn-
aptic pathology in Alzheimer’s disease is the direct
result of an underlying molecular defect a¡ecting the
synapses, or an indirect result from neuronal loss,
plaque and tangle formation, the eventual degenera-
tion of synapses in the Alzheimer’s patients probably
contributes to the overall degenerative process
[50,51].
Although the molecular mechanisms of synaptic
damage in Alzheimer’s disease pathogenesis are not
clearly understood, possible mechanisms include: (1)
abnormal function of some synaptic protein, (2) di-
rect toxic e¡ects of toxins on the presynaptic site, (3)
abnormal accumulation of aberrantly processed syn-
aptic proteins at the nerve junction, or (4) some com-
bination of these factors. Masliah et al. have pro-
posed that abnormal expression of growth-
associated proteins in the central nervous system
may play a role in this mechanism [51,52]. Prominent
molecules among these are APP [53], apolipoprotein
E (ApoE) [54], presenilin(s) [55] and NACP/K-synu-
clein [43]. All these molecules have several common
features: (1) possible ability to modulate synaptic
function, (2) involvement in amyloidogenesis and
(3) mutations (e.g. APP, presenilin) and polymor-
phisms (e.g. ApoE, NACP/K-synuclein) that are as-
sociated with a higher risk for developing Alzheim-
er’s disease [43].
In summary, synaptic pathology related to the al-
teration of synaptic proteins is an essential change
found in brain tissue of Alzheimer’s disease patients.
Additionally, several synaptic molecules such as APP
are associated with not only synaptic function but
amyloid formation.
3. NACP/K-synuclein and Alzheimer’s disease
NAC was originally found in the amyloid-enriched
fraction of brain homogenates of Alzheimer’s disease
patients [6]. It was copuri¢ed with AL and comprised
10% of the protein in the SDS-insoluble tissue frac-
tion by mass. It was sequenced biochemically [6],
Fig. 2. Morphologic evidence indicating NAC is present in amyloid. (A) NAC immunostaining in amyloid was found in brain tissue
from an Alzheimer’s disease patient. Anti-NAC antibody stained amyloid in the core of senile plaques contained in tissue from the
midfrontal cerebral cortex. The scale bar represents 15 Wm. (B) The same amyloid stains positive after thio£avin-S staining (taken
from Ref. [61]).
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which makes NAC unique from other amyloid-asso-
ciated components which can be detected only by
immunological methods. Additionally, antisera
raised against NAC stained senile plaque amyloid
(Fig. 2). Taken together, these results suggest that
NAC is tightly associated with AL and may have a
role in amyloidogenesis in Alzheimer’s disease pa-
tients [6].
However, recent reports have raised questions re-
garding the presence of NAC in amyloid plaques.
Bayer et al. and Culvenor et al. showed that no
NAC immunoreactivity was detected in Alzheimer’s
disease plaques [56,57]. It has been suggested that
one reason for such contradictory results in histo-
chemical studies may be di¡erences in brain sample
preparation. It should be noted that mildly ¢xed
brain samples with 2% bu¡ered paraformaldehyde
and prepared using a vibratome are required to de-
tect NAC immunoreactivity in amyloid plaques [6].
However, in addition to histopathological research,
Culvenor et al. detected a 6 kDa fragment using an
anti-NAC antibody, but could not detect fragments
corresponding to the 3.5 kDa-NAC peptide in the
SDS-insoluble, urea-soluble fraction in which AL
was detected, indicating the absence of NAC in a
protein fraction containing AL [57]. Consequently,
it is necessary to verify whether NAC is contained
in the fraction in which all essential constituents of
amyloid proteins are extracted, because proteins ex-
tracted using the SDS-insoluble, urea-soluble tech-
nique might be di¡erent from those extracted using
the formic acid technique which Ue¤da used to isolate
NAC fragments [6]. Since this is one of the most
important subjects to elucidate how NACP/K-synu-
clein is involved in the pathogenesis of Alzheimer’s
disease, further investigation about the properties
of anti-NAC antibodies, the condition of brain sec-
tions and biochemical analysis of proteins constitut-
ing the amyloid plaques is needed to resolve this
dispute.
Nevertheless, assuming for the moment that NAC
colocalizes with AL in Alzheimer’s disease amyloid,
the role of NAC and NACP/K-synuclein in the for-
mation of amyloid plaques has been investigated.
NACP/K-synuclein binds to AL and enhances AL
amyloid formation [58]. The dominant binding site
on NACP/K-synuclein is the region from residues 81
to 95, and that on AL is the region from residues 25
to 35. These observations are interesting since mole-
cules such as ApoE, K1-antichymotrypsin and com-
plement protein C1q were reported to bind to the
AL1^28 region. Therefore, NACP/K-synuclein ap-
pears to be the ¢rst molecule known to bind the
AL25^35 region and to promote AL aggregation
[58]. Although it remains possible that additional
portions of NACP/K-synuclein are present in amy-
loid, the amount of such fragments would be quite
small since antibodies to the C and N terminus of the
full-length protein did not detect any immunoreactiv-
ity in plaques, suggesting that the NAC portion
alone is the essential fragment present in Alzheimer’s
disease amyloid [59,60]. The NAC fragment is amy-
loidogenic itself, and can form amyloid ¢brils that in
turn increase AL amyloid formation [61,62]. In addi-
tion, antibodies to the NAC domain detect the pep-
tide more frequently in mature rather than di¡use
plaques and in the plaque core rather than at the
periphery [59]. These data suggest that both NAC
and NACP/K-synuclein accelerate the aggregation
of AL peptide by nucleation. Additionally, Jensen
et al. reported that transglutaminase catalyzed
homo-dimer forms of NAC and hetero-tetramer
forms of NAC and AL, indicating that amino acid
modi¢cation may a¡ect the amyloid forming poten-
tial of the peptide [63].
NACP/K-synuclein may also contribute to aber-
rant synapse formation in the brain of Alzheimer’s
disease patients. Masliah et al. found a signi¢cant
increase in the intensity of NACP/K-synuclein stain-
ing in individual synaptic boutons from the brains of
Alzheimer’s disease patients compared with those of
patients without the disease [59]. In contrast, no
measurable change in staining intensity was found
for synaptophysin, another presynaptic-speci¢c pro-
tein [59]. Additionally, while the number of synapses
detected by synaptophysin staining decreased, the
NACP/K-synuclein signal intensity per synaptic bou-
ton increased. Ultimately, Masliah et al. found that
the ratio of NACP/K-synuclein to synaptophysin in
Alzheimer’s disease patients is twice as great as in
control patients [59]. Pathological observation re-
vealed these synaptic boutons were distorted by
swelling, and the accumulation of NACP/K-synuclein
at the presynaptic site is found even in early stages of
Alzheimer’s disease [64] (Fig. 3). Interestingly, sev-
eral dystrophic neurites were also detected by
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NACP/K-synuclein staining [59,64]. These data sug-
gest that aberrant accumulation of NACP/K-synu-
clein at the presynaptic terminal is an early event
in the pathogenesis of Alzheimer’s disease, which
may possibly cause synaptic degeneration.
No NACP/K-synuclein mutations directly linked
to familial Alzheimer’s disease have been found
thus far [13,65]. Xia et al. have found that one allele,
Allele 2, of a dinucleotide repeat ([TC]12N5[TC]-
9[AT]7[AC]12) polymorphism in the promoter of
the gene is signi¢cantly over-represented in healthy
elderly individuals at a risk of Alzheimer’s disease
due to the ApoE genotype Allele O4, indicating a
possible protective function of this allele [13]. How-
ever, Hellman et al. failed to demonstrate any pro-
tection conferred by Allele 2 [66]. Further investiga-
tion is required to prove what role, if any, this
polymorphism plays in Alzheimer’s disease patho-
genesis.
Considering this evidence, NACP/K-synuclein
seems to play an important role in both amyloid
formation and synaptic change. Since the mecha-
nisms of how this protein contributes to both these
changes are still unknown, they remain the subject of
intense investigation.
4. A mutant NACP/K-synuclein causes one type of
familial Parkinson’s disease and Lewy bodies
contain NACP/K-synuclein
Recently, mutant forms of NACP/K-synuclein
have gained much attention as possible causal factors
for developing Parkinson’s disease. In 1997, Poly-
meropoulos et al. reported the identi¢cation of a
missense mutation in the NACP/K-synuclein gene in
Italian and Greek families with early-onset of Par-
kinson’s disease and this mutation could cause a sub-
stitution of amino acid T53 for A53 [67]. The follow-
ing year, another missense mutation, of amino acid
P30 for A30, was reported in a German family with
familial Parkinson’s disease [68]. These ¢ndings im-
ply that NACP/K-synuclein may play a primary role
in the pathogenesis of Parkinson’s disease.
In addition to these ¢ndings, the Lewy bodies
found in patients with both sporadic Parkinson’s dis-
ease and dementia with Lewy bodies were stained
strongly with anti-NACP/K-synuclein antibodies
[69^73]. Baba et al. showed that NACP/K-synuclein,
but not L-synuclein, accumulated in Lewy bodies
with decorating ¢laments and granular materials in
it, and that not only full-length, but also partially
Fig. 3. Patterns of NACP/K-synuclein and APP immunoreactivity in the middle temporal gyrus of cerebral cortical tissue from pa-
tients with or without Alzheimer’s disease. A polyclonal antiserum against the C-terminal region (131^140) of NACP/K-synuclein was
used to immunolabel the presynaptic boutons in (A) control patients, (B) and (C) patients with Alzheimer’s disease. (B) Several neu-
rons are severely distended and display strong immunoreactivity at what appear to be dystrophic neurites (arrows). (C) Accumulation
of APP was also observed in dystrophic neurites as determined by staining with the APP monoclonal antibody 22C11 (shown by ar-
rows). The length of the scale bar represents 50 Wm.
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truncated forms of this protein were present in Lewy
bodies [71]. Dementia with Lewy bodies is an espe-
cially important case to study, because both Lewy
bodies including NACP/K-synuclein [69,71^73] and
amyloid containing NAC are present in these pa-
tients [72]. Recently, Lippa et al. reported that
Lewy bodies in brain tissue from many familial Alz-
heimer’s disease patients with mutations in presenilin
and APP genes contained NACP/K-synuclein [74]. In
contrast, neuro¢brillary tangles, neuropil threads,
Pick bodies, ballooned neurons and glial tangles
(most of which were tau positive) were NACP/K-syn-
uclein negative, supporting the view that NACP/K-
synuclein speci¢cally accumulates in diseases related
to Lewy bodies [75] and suggesting that the ability of
NACP/K-synuclein to cause protein aggregation may
underlie the pathogenesis of Lewy body formation.
However, while the NAC portion tends to form a
L-sheet structure which may easily cause aggregation,
structural analyses have shown that the native form
of NACP/K-synuclein is unfolded and elongated
[23,76]. This suggests the hypothesis that the mecha-
nism of NACP/K-synuclein aggregation is di¡erent
from typical amyloid ¢bril formation, which depends
on the formation of a L-sheet structure. Yoshimoto
et al. has shown that NACP/K-synuclein forms
dimers during incubation [58], suggesting this protein
may interact with itself, while other studies have
shown self-aggregation of this protein promotes ¢bril
formation [77^80]. Crowther et al. reported that
NACP/K-synuclein truncated at the C-terminus read-
ily assembles into ¢laments resembling those isolated
from diseased brain tissue, suggesting that proteo-
lytic truncation may play a role in the pathological
process of NACP/K-synuclein aggregation [79]. Fi-
nally, Narhi et al. revealed that NACP/K-synuclein
with the mutation T53 for A53 most readily pro-
moted protein aggregation, followed by NACP/K-
synuclein carrying the mutation of P30 for A30,
while wild type NACP/K-synuclein has the lowest
of all three NACP/K-synucleins [80]. The mechanism
of how NACP/K-synuclein ¢brils become intracellu-
larly toxic to the neurons is still unknown. In neuro-
degenerative diseases accompanied by Lewy body
formation, such inclusion bodies may act as intra-
cellular toxins interrupting axonal transport, sup-
pressing organelle functions in neurons or inducing
energy failure caused by hyper-ubiquitination of the
constituents in the Lewy bodies.
Recently, inclusion bodies composed of NACP/K-
synuclein have been found not only in neurons but in
glial cells. Glial cytoplasmic inclusions containing in-
soluble NACP/K-synuclein also have been reported
in white matter oligodendrocytes of patients with
multiple system atrophy [81,82]. Since NACP/K-syn-
uclein is produced almost exclusively by neurons, the
route by which NACP/K-synuclein ¢nds its way into
glial cell inclusion bodies is unknown. One possibility
is that glial cells themselves produce a small amount
of this protein while another is that NACP/K-synu-
clein released from neurons is taken up by the glial
cells. If this inclusion of NACP/K-synuclein also
plays a role in glial cell toxicity, a common mecha-
nism probably underlies both neuronal toxicity in
Lewy body-related neurodegenerative disease and
glial cell toxicity in multiple system atrophy.
C
Fig. 4. An hypothesis of how NACP/K-synuclein is related to the pathogenesis of Alzheimer’s disease. (A) In normal brain tissue,
NACP/K-synuclein is transferred to the synaptic terminal, assembled on the surface of the synaptic vesicle and associated with the syn-
aptic functions including plasticity. (B) In brain tissue from persons with Alzheimer’s disease, (1) NACP/K-synuclein and APP accu-
mulate at the synaptic site by missorting (causal) or increased expression (responsive). (2) Aberrant accumulation of such synaptic pro-
tein may act as intracellular toxins themselves. Uncontrolled NACP/K-synuclein and APP might disrupt synaptic function, leading to
dementia. (3) Misfolded NACP/K-synuclein in the cytoplasm forms Lewy bodies which disrupt intracellular function. If NAC is in a
component of Alzheimer’s disease amyloid, the following mechanism can be proposed. (4) Increased APP amount leads to an in-
creased concentration of AL around the synapse. (5) The AL begins to form ‘seeds’ of amyloid on or in the plasma membrane. (6)
NACP/K-synuclein may bind to AL in the vicinity of the membrane and promote amyloid formation. (7) The NACP/K-synuclein
bound to AL is processed by unknown proteases, resulting in NAC fragments in the amyloid. (8) Polymerized AL and NAC build up,
becoming toxic to the neuron. This toxicity disrupts turnover of NACP/K-synuclein and APP, consequently both proteins would accu-
mulate again at the synaptic site and generate amyloidogenic fragments.
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5. Hypotheses: how does NACP/K-synuclein
contribute to the development of Alzheimer’s
disease?
In Alzheimer’s disease patients, NACP/K-synuclein
and APP accumulate abnormally at presynaptic sites,
marking the early distinguished event in Alzheimer’s
disease pathogenesis [59,64,75]. Interestingly, both
APP and NACP/K-synuclein are thought to be asso-
ciated with both synaptic function and amyloid for-
mation as described previously [28,83,84]. From this
evidence, two hypotheses can be proposed.
The ¢rst is that the regulation and turnover of
such important proteins at the synapse initially fail
due to an undisclosed mechanism. Synaptic dysfunc-
tion resulting in dementia develops as the proteins
accumulate at or near the synapse and form amyloid.
In this hypothesis, abnormal accumulation of partic-
ular synaptic proteins directly causes the pathology.
A recent report suggests that alteration of cholesterol
regulation, possibly by ApoE and its receptor LRP,
may be related to missorting or abnormal turnover
of synaptic proteins such as APP [85]. Such aberrant
accumulation of synaptic proteins may act as intra-
cellular toxins, interrupting intracellular function.
The second hypothesis posits that after an unknown
stress damages synapses, the synthesis of proteins
increases to maintain and support the lost synaptic
function. However, this increased synthesis is either
insu⁄cient to compensate for the damage or unbal-
ances synaptic protein homeostasis, inducing amy-
loid formation and dementia. The ¢nding that
NACP/K-synuclein synthesis increases in brains suf-
fering from ischemic insult supports this idea [86].
According to this hypothesis, abnormal accumula-
tion of synaptic proteins is a consequence of disease
progression, not a cause. In this case, AL ¢brils
might act as neuronal toxins [87]. Both hypotheses
propose that aggregates of NACP/K-synuclein, or
NAC fragments, at synapse may harm neurons
through a mechanism similar to that associated
with AL aggregates [88]. If so, aberrant accumulation
of synaptic proteins and amyloid-inducing neuronal
toxicity could act reciprocally.
Although it has recently been called into question
whether the NAC fragment is contained in AL-con-
taining amyloid, if NAC is one component of Alz-
heimer’s disease amyloid, the following mechanism
describes a presumptive pathological cascade.
Although the details concerning association of either
NACP/K-synuclein or NAC with AL is unclear, in
vitro experiments have demonstrated that AL binds
to the NAC portion of NACP/K-synuclein [58]. Since
NACP/K-synuclein is probably located in the cyto-
plasm, due to its lack of a signal peptide, it is un-
likely that NACP/K-synuclein would directly contact
AL found (and probably generated by L- and Q-sec-
retase) in vesicles such as endosomes or secretory
vesicles [89]. It is assumed that the site where the
presynaptic vesicle membrane fuses with the plasma
membrane is the place at which both molecules come
into contact. The site at which AL binds to NACP/K-
synuclein is known to be between residues G25 to
M35, half of which, residues G29 to M35, is buried
in the membrane [90]. It has been reported that a
possible form of pre-amyloid in Alzheimer’s disease
is membrane-bound AL which binds to the GM1
ganglioside molecule of the membrane [91,92] and
is found in the detergent-insoluble membrane com-
ponent [93,94]. Other results show that AL interacts
with lipid, thus involving either the cell membrane or
the intracellular vesicular system [95]. These ¢ndings
indicate that the place where amyloid formation
starts is on or in plasma membranes. Additionally,
NACP/K-synuclein binds to small unilamellar phos-
pholipid vesicles in vitro [24]. These results support
the idea that the membranes serve as a rendezvous
point for both molecules. After NACP/K-synuclein
and AL form a complex, the N- and C-terminals of
NACP/K-synuclein might be digested by unidenti¢ed
protease(s), and the digested NACP/K-synuclein
forms the seeds of AL amyloid ¢bril formation and
enhances amyloid elongation [61]. This putative cas-
cade is illustrated in Fig. 4.
Finally the author would like to introduce a
unique idea proposed by the late Tsunao Saitoh,
who was a pioneer in NACP/K-synuclein research.
His concept was that amyloid formation might be a
neuronal protection mechanism. Toxic forms of AL
are thought to be the so-called ‘proto¢brillar AL’,
which consists of small oligomers of AL, and proto-
¢brils directly contact neurons [96]. However, an ex-
cess aggregation of the molecules would become less
toxic because large ¢brils cannot approach neurons
and their unknown binding sites. Therefore, an an-
cillary function of factors such as NAC or NACP/K-
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synuclein may be to rescue neurons by promoting the
formation of large amyloid deposits from toxic pro-
to¢brillar AL. If so, NAC or NACP/K-synuclein
could be regarded as ‘a sweeper’ of harmful AL,
and is induced when neurons su¡er damage. This
view challenges the conventional understanding of
‘amyloid’, but is well worth consideration.
6. Concluding remarks
The precursor protein of a constituent of Alzheim-
er’s disease amyloid, NACP/K-synuclein, appears to
be an important molecule in presynaptic terminal
function, in£uencing synaptic plasticity like APP.
The abnormal function of NACP/K-synuclein, result-
ing in self-aggregation, appears to play a signi¢cant
role in the pathogenesis of Alzheimer’s disease and
other neurodegenerative diseases. Consequently,
analysis of this protein will doubtlessly provide val-
uable insights into neurodegenerative disease.
7. Note added in proof
Recently, inclusion bodies of NACP/K-synuclein
were found in the neocortex, hippocampus, and sub-
stantia nigra of the NACP/K-synuclein transgenic
mouse by Masliah et al. [E. Masliah, E. Rockenstein,
I. Veinbergs, M. Mallory, M. Hashimoto, A. Take-
da, Y. Sagara, A. Sisk, L. Mucke, Science 287 (2000)
1265^1269]. Feany et al. expressed normal and mu-
tant forms of NACP/K-synuclein in Drosophila and
produced adult-onset loss of dopaminergic neurons,
¢lamentous intraneuronal inclusions containing
NACP/K-synuclein and locomotor dysfunction
[M.B. Feany, W.W. Bender, Nature 404 (2000)
394^398]. In addition, Murphy et al. showed one
function of NACP/K-synuclein may be to regulate
the size of distinct pools of synaptic vesicles in ma-
ture neurons [D.D. Murphy, S.M. Rueter, J.Q. Tro-
janowski, V.M.-Y. Lee, J. Neurosci. 20 (2000) 3214^
3220].
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